journal article·2024-06-05

Engineering brain-on-a-chip platforms

Bram Servais, Negar Mahmoudi, Vini Gautam, Wei Tong, Michael R. Ibbotson, David R. Nisbet, David Collins

Nature Reviews Bioengineering· Volume 2· Issue 8
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Neuroscience and Neural Engineering · EEG and Brain-Computer Interfaces · Molecular Communication and Nanonetworks

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).10.1016/S2468-2667(21)00249-8 ↗
2. Feigin, V. L. et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459–480 (2019).10.1016/S1474-4422(18)30499-X ↗
3. Velandia, P. P. et al. Global and regional spending on dementia care from 2000–2019 and expected future health spending scenarios from 2020–2050: an economic modelling exercise. EClinicalMedicine 45, 101337 (2022).10.1016/j.eclinm.2022.101337 ↗
4. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9, 137–150 (2022).10.1016/S2215-0366(21)00395-3 ↗
5. Pollak, T. A. et al. The blood–brain barrier in psychosis. Lancet Psychiatry 5, 79–92 (2018).10.1016/S2215-0366(17)30293-6 ↗
6. McCutcheon, R. A., Reis Marques, T. & Howes, O. D. Schizophrenia — an overview. JAMA Psychiatry 77, 201 (2020).10.1001/jamapsychiatry.2019.3360 ↗
7. Millan, M. J. et al. Altering the course of schizophrenia: progress and perspectives. Nat. Rev. Drug Discov. 15, 485–515 (2016).10.1038/nrd.2016.28 ↗
8. McNally, J. M. & McCarley, R. W. Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. Curr. Opin. Psychiatry 29, 202–210 (2016).10.1097/YCO.0000000000000244 ↗
9. Sweeney, M. D., Sagare, A. P. & Zlokovic, B. V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 14, 133–150 (2018).10.1038/nrneurol.2017.188 ↗
10. Canter, R. G., Penney, J. & Tsai, L. H. The road to restoring neural circuits for the treatment of Alzheimer’s disease. Nature 539, 187–196 (2016).10.1038/nature20412 ↗
11. Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Primers 7, 33 (2021).10.1038/s41572-021-00269-y ↗
12. Hampel, H. et al. The amyloid-β pathway in Alzheimer’s disease. Mol. Psychiatry 26, 5481–5503 (2021).10.1038/s41380-021-01249-0 ↗
13. Tzioras, M., McGeachan, R. I., Durrant, C. S. & Spires-Jones, T. L. Synaptic degeneration in Alzheimer disease. Nat. Rev. Neurol. 19, 19–38 (2023).10.1038/s41582-022-00749-z ↗
14. Hosoki, S. et al. Molecular biomarkers for vascular cognitive impairment and dementia. Nat. Rev. Neurol. 19, 737–753 (2023).10.1038/s41582-023-00884-1 ↗
15. Perovnik, M., Rus, T., Schindlbeck, K. A. & Eidelberg, D. Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nat. Rev. Neurol. 19, 73–90 (2023).10.1038/s41582-022-00753-3 ↗
16. Arrowsmith, J. Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 10, 328–329 (2011).10.1038/nrd3439 ↗
17. Arrowsmith, J. Phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov. 10, 87 (2011).10.1038/nrd3375 ↗
18. Arrowsmith, J. & Miller, P. Phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).10.1038/nrd4090 ↗
19. Smietana, K., Siatkowski, M. & Møller, M. Trends in clinical success rates. Nat. Rev. Drug Discov. 15, 379–380 (2016).10.1038/nrd.2016.85 ↗
20. Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049–3062 (2022).10.1016/j.apsb.2022.02.002 ↗
21. Butlen-Ducuing, F. et al. Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective. Nat. Rev. Drug Discov. 15, 813–814 (2016).10.1038/nrd.2016.237 ↗
22. Kesselheim, A. S., Hwang, T. J. & Franklin, J. M. Two decades of new drug development for central nervous system disorders. Nat. Rev. Drug Discov. 14, 815–816 (2015).10.1038/nrd4793 ↗
23. Gribkoff, V. K. & Kaczmarek, L. K. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120, 11–19 (2017).10.1016/j.neuropharm.2016.03.021 ↗
24. Danon, J. J., Reekie, T. A. & Kassiou, M. Challenges and opportunities in central nervous system drug discovery. Trends Chem. 1, 612–624 (2019).10.1016/j.trechm.2019.04.009 ↗
25. Paul, S. M. et al. How to improve RD productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9, 203–214 (2010).10.1038/nrd3078 ↗
26. Han, J. J. FDA modernization Act 2.0 allows for alternatives to animal testing. Artif. Organs 47, 449–450 (2023).10.1111/aor.14503 ↗
27. Stewart, A., Denoyer, D., Gao, X. & Toh, Y.-C. The FDA modernisation act 2.0: bringing non-animal technologies to the regulatory table. Drug Discov. Today 28, 103496 (2023).10.1016/j.drudis.2023.103496 ↗
28. Franzen, N. et al. Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov. Today 24, 1720–1724 (2019).10.1016/j.drudis.2019.06.003 ↗
29. Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P. & Tagle, D. A. Organs-on-chips: into the next decade. Nat. Rev. Drug Discov. 20, 345–361 (2021).10.1038/s41573-020-0079-3 ↗
30. Stresser, D. M. et al. Towards in vitro models for reducing or replacing the use of animals in drug testing. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01154-7 (2023).10.1038/s41551-023-01154-7 ↗
31. Li, T. L. et al. Stretchable mesh microelectronics for the Biointegration and stimulation of neural organoids. Biomaterials 290, 121825 (2022).10.1016/j.biomaterials.2022.121825 ↗
32. Floch, P. L. et al. Stretchable mesh nanoelectronics for 3D single-cell chronic electrophysiology from developing brain organoids. Adv. Mater. 34, e2106829 (2022).10.1002/adma.202106829 ↗
33. Yang, X. et al. Kirigami electronics for long-term electrophysiological recording of human neural organoids and assembloids. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-02081-3 (2024).10.1038/s41587-023-02081-3 ↗
34. Li, Q. et al. Cyborg organoids: implantation of nanoelectronics via organogenesis for tissue-wide electrophysiology. Nano Lett. 19, 5781–5789 (2019). This article reports flexible electronics that can be wrapped into tissue models during cell aggregation.10.1021/acs.nanolett.9b02512 ↗
35. Skylar-Scott, M. A. et al. Orthogonally induced differentiation of stem cells for the programmatic patterning of vascularized organoids and bioprinted tissues. Nat. Biomed. Eng. 6, 449–462 (2022).10.1038/s41551-022-00856-8 ↗
36. You, S. et al. High cell density and high-resolution 3D bioprinting for fabricating vascularized tissues. Sci. Adv. 9, eade7923 (2023).10.1126/sciadv.ade7923 ↗
37. Wang, Y. et al. Peptide programmed hydrogels as safe sanctuary microenvironments for cell transplantation. Adv. Funct. Mater. 30, 1900390 (2020).10.1002/adfm.201900390 ↗
38. Law, K. C. L. et al. A selective, hydrogel‐based prodrug delivery system efficiently activates a suicide gene to remove undifferentiated human stem cells within neural grafts. Adv. Funct. Mater. 33, 2305771 (2023).10.1002/adfm.202305771 ↗
39. Nakatsuka, N. et al. Aptamer–field-effect transistors overcome Debye length limitations for small-molecule sensing. Science 362, 319–324 (2018). This article reports aptamer–field-effect transistors combining the versatility of an aptamer bio-recognition element with the high sensitivity of field-effect transistors.10.1126/science.aao6750 ↗
40. Nakatsuka, N. et al. Sensing serotonin secreted from human serotonergic neurons using aptamer-modified nanopipettes. Mol. Psychiatry 26, 2753–2763 (2021).10.1038/s41380-021-01066-5 ↗
41. Zhao, C. et al. Implantable aptamer–field-effect transistor neuroprobes for in vivo neurotransmitter monitoring. Sci. Adv. 7, eabj7422 (2021).10.1126/sciadv.abj7422 ↗
42. Abbott, N. J. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol. Neurobiol. 25, 5–23 (2005).10.1007/s10571-004-1374-y ↗
43. Kasinathan, N., Jagani, H. V., Alex, A. T., Volety, S. M. & Venkata Rao, J. Strategies for drug delivery to the central nervous system by systemic route. Drug Deliv. 22, 243–257 (2015).10.3109/10717544.2013.878858 ↗
44. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRX 2, 3–14 (2005).10.1602/neurorx.2.1.3 ↗
45. Sierra, S. et al. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J. Alzheimer’s Dis. 23, 307–318 (2011).10.3233/JAD-2010-101179 ↗
46. Wolff, A., Antfolk, M., Brodin, B. & Tenje, M. In vitro blood-brain barrier models — an overview of established models and new microfluidic approaches. J. Pharm. Sci. 104, 2727–2746 (2015).10.1002/jps.24329 ↗
47. Liu, C. C. et al. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nat. Neurosci. 25, 1020–1033 (2022).10.1038/s41593-022-01127-0 ↗
48. Chuapoco, M. R. et al. Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. Nat. Nanotechnol. 18, 1241–1251 (2023).10.1038/s41565-023-01419-x ↗
49. Chen, X. et al. Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates. Nat. Commun. 14, 3345 (2023).10.1038/s41467-023-38582-7 ↗
50. Zhang, S. L., Yue, Z., Arnold, D. M., Artiushin, G. & Sehgal, A. A circadian clock in the blood-brain barrier regulates xenobiotic efflux. Cell 173, 130–139.e10 (2018).10.1016/j.cell.2018.02.017 ↗
51. Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates. Nat. Biomed. Eng. 6, 1257–1271 (2022).10.1038/s41551-022-00938-7 ↗
52. Wang, P. et al. Blood–brain barrier injury and neuroinflammation induced by SARS-CoV-2 in a lung–brain microphysiological system. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01054-w (2023).10.1038/s41551-023-01054-w ↗
53. Padmanabhan, P. & Götz, J. Clinical relevance of animal models in aging-related dementia research. Nat. Aging 3, 481–493 (2023).10.1038/s43587-023-00402-4 ↗
54. McClain, S. P. et al. In vivo photopharmacology with light-activated opioid drugs. Neuron 111, 3926–3940.e10 (2023).10.1016/j.neuron.2023.09.017 ↗
55. Chung, J. E. et al. High-density single-unit human cortical recordings using the Neuropixels probe. Neuron 110, 2409–2421.e3 (2022).10.1016/j.neuron.2022.05.007 ↗
56. Luo, T. Z. et al. An approach for long-term, multi-probe neuropixels recordings in unrestrained rats. eLife 9, e59716 (2020).10.7554/eLife.59716 ↗
57. van Daal, R. J. J. et al. Implantation of Neuropixels probes for chronic recording of neuronal activity in freely behaving mice and rats. Nat. Protoc. 16, 3322–3347 (2021).10.1038/s41596-021-00539-9 ↗
58. Steinmetz, N. A. et al. Neuropixels 2.0: a miniaturized high-density probe for stable, long-term brain recordings. Science 372, eabf4588 (2021). The article reports one of the highest-density probes, which can record densely packed neurons across multiple cortical layers.10.1126/science.abf4588 ↗
59. Ji, B. et al. Flexible and stretchable opto-electric neural interface for low-noise electrocorticogram recordings and neuromodulation in vivo. Biosens. Bioelectron. 153, 112009 (2020).10.1016/j.bios.2020.112009 ↗
60. Obaid, A. et al. Massively parallel microwire arrays integrated with CMOS chips for neural recording. Sci. Adv. 6, eaay2789 (2020).10.1126/sciadv.aay2789 ↗
61. Leber, M. et al. in Neural Interface: Frontiers and Applications (ed. Zheng, X.) Ch. 1 (Springer, 2019). [Series Eds Crusio, W. E. et al. Advances in Experimental Medicine and Biology Vol. 1101].
62. Holmes, A., Bonner, F. & Jones, D. Assessing drug safety in human tissues-what are the barriers? Nat. Rev. Drug Discov. 14, 585–587 (2015).10.1038/nrd4662 ↗
63. Haring, A. P., Sontheimer, H. & Johnson, B. N. Microphysiological human brain and neural systems-on-a-chip: potential alternatives to small animal models and emerging platforms for drug discovery and personalized medicine. Stem Cell Rev. Rep. 13, 381–406 (2017).10.1007/s12015-017-9738-0 ↗
64. Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat. Biotechnol. 32, 760–772 (2014).10.1038/nbt.2989 ↗
65. Hajal, C., Le Roi, B., Kamm, R. D. & Maoz, B. M. Biology and models of the blood-brain barrier. Annu. Rev. Biomed. Eng. 23, 359–384 (2021).10.1146/annurev-bioeng-082120-042814 ↗
66. Bang, S., Lee, S., Choi, N. & Kim, H. N. Emerging brain-pathophysiology-mimetic platforms for studying neurodegenerative diseases: brain organoids and brains-on-a-chip. Adv. Healthc. Mater. 10, e202002119 (2021).10.1002/adhm.202002119 ↗
67. Iadecola, C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron 96, 17–42 (2017).10.1016/j.neuron.2017.07.030 ↗
68. Hong, G. & Lieber, C. M. Novel electrode technologies for neural recordings. Nat. Rev. Neurosci. 20, 330–345 (2019).10.1038/s41583-019-0140-6 ↗
69. Jun, J. J. et al. Fully integrated silicon probes for high-density recording of neural activity. Nature 551, 232–236 (2017).10.1038/nature24636 ↗
70. Son, Y. et al. In vivo optical modulation of neural signals using monolithically integrated two-dimensional neural probe arrays. Sci. Rep. 5, 15466 (2015).10.1038/srep15466 ↗
71. Paulk, A. C. et al. Large-scale neural recordings with single neuron resolution using Neuropixels probes in human cortex. Nat. Neurosci. 25, 252–263 (2022).10.1038/s41593-021-00997-0 ↗
72. Canales, A. et al. Multifunctional fibers for simultaneous optical, electrical and chemical interrogation of neural circuits in vivo. Nat. Biotechnol. 33, 277–284 (2015).10.1038/nbt.3093 ↗
73. Kuzum, D. et al. Transparent and flexible low noise graphene electrodes for simultaneous electrophysiology and neuroimaging. Nat. Commun. 5, 5259 (2014).10.1038/ncomms6259 ↗
74. Khodagholy, D. et al. NeuroGrid: recording action potentials from the surface of the brain. Nat. Neurosci. 18, 310–315 (2015).10.1038/nn.3905 ↗
75. Park, J. S. et al. A multimodality CMOS sensor array for cell-based assay and drug screening. Dig. Tech. Pap. IEEE Int. Solid. State Circuits Conf. 58, 208–209 (2015).
76. Miccoli, B. et al. High-density electrical recording and impedance imaging with a multi-modal CMOS multi-electrode array chip. Front. Neurosci. 13, 641 (2019).10.3389/fnins.2019.00641 ↗
77. Wen, X. et al. Flexible, multifunctional neural probe with liquid metal enabled, ultra-large tunable stiffness for deep-brain chemical sensing and agent delivery. Biosens. Bioelectron. 131, 37–45 (2019).10.1016/j.bios.2019.01.060 ↗
78. Huang, Q. et al. Shell microelectrode arrays (MEAs) for brain organoids. Sci. Adv. 8, eabq5031 (2022).10.1126/sciadv.abq5031 ↗
79. Cools, J. et al. A micropatterned multielectrode shell for 3D spatiotemporal recording from live cells. Adv. Sci. 5, 1700731 (2018).10.1002/advs.201700731 ↗
80. Shin, H. et al. 3D high-density microelectrode array with optical stimulation and drug delivery for investigating neural circuit dynamics. Nat. Commun. 12, 492 (2021).10.1038/s41467-020-20763-3 ↗
81. Ryynänen, T. et al. Microelectrode array with transparent ALD TiN electrodes. Front. Neurosci. 13, 226 (2019).10.3389/fnins.2019.00226 ↗
82. Kshirsagar, P. et al. Transparent graphene/PEDOT:PSS microelectrodes for electro- and optophysiology. Adv. Mater. Technol. 4, 1800318 (2019).10.1002/admt.201800318 ↗
83. Susloparova, A. et al. Low impedance and highly transparent microelectrode arrays (MEA) for in vitro neuron electrical activity probing. Sens. Actuators B Chem. 327, 128895 (2021).10.1016/j.snb.2020.128895 ↗
84. Wang, Y. I., Abaci, H. E. & Shuler, M. L. Microfluidic blood–brain barrier model provides in vivo‐like barrier properties for drug permeability screening. Biotechnol. Bioeng. 114, 184–194 (2017).10.1002/bit.26045 ↗
85. Maoz, B. M. et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat. Biotechnol. 36, 865–877 (2018).10.1038/nbt.4226 ↗
86. Salmon, I. et al. Engineering neurovascular organoids with 3D printed microfluidic chips. Lab. Chip 22, 1615–1629 (2022).10.1039/D1LC00535A ↗
87. Zhang, S., Wan, Z. & Kamm, R. D. Vascularized organoids on a chip: strategies for engineering organoids with functional vasculature. Lab. Chip 21, 473–488 (2021).10.1039/D0LC01186J ↗
88. Campisi, M. et al. 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. Biomaterials 180, 117–129 (2018). This article reports a foundational microfluidic BBB model with self-assembled vasculature highlighting the strong remodelling characteristics of these tissue models.10.1016/j.biomaterials.2018.07.014 ↗
89. Muoio, V., Persson, P. B. & Sendeski, M. M. The neurovascular unit–concept review. Acta Physiol. 210, 790–798 (2014).10.1111/apha.12250 ↗
90. Choublier, N. et al. Exposure of human cerebral microvascular endothelial cells hCMEC/D3 to laminar shear stress induces vascular protective responses. Fluids Barriers CNS 19, 41 (2022).10.1186/s12987-022-00344-w ↗
91. Reinitz, A., DeStefano, J., Ye, M., Wong, A. D. & Searson, P. C. Human brain microvascular endothelial cells resist elongation due to shear stress. Microvasc. Res. 99, 8–18 (2015).10.1016/j.mvr.2015.02.008 ↗
92. Mehta, A. et al. Bio-mimicking brain vasculature to investigate the role of heterogeneous shear stress in regulating barrier integrity. Adv. Biol. 6, e2200152 (2022).10.1002/adbi.202200152 ↗
93. DeStefano, J. G., Xu, Z. S., Williams, A. J., Yimam, N. & Searson, P. C. Effect of shear stress on iPSC-derived human brain microvascular endothelial cells (dhBMECs). Fluids Barriers CNS 14, 20 (2017).10.1186/s12987-017-0068-z ↗
94. Garcia-Polite, F. et al. Pulsatility and high shear stress deteriorate barrier phenotype in brain microvascular endothelium. J. Cereb. Blood Flow. Metab. 37, 2614–2625 (2017).10.1177/0271678X16672482 ↗
95. Park, T. E. et al. Hypoxia-enhanced blood-brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat. Commun. 10, 2621 (2019).10.1038/s41467-019-10588-0 ↗
96. Wevers, N. R. et al. A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. Fluids Barriers CNS 15, 23 (2018).10.1186/s12987-018-0108-3 ↗
97. Huh, D. et al. Microfabrication of human organs-on-chips. Nat. Protoc. 8, 2135–2157 (2013).10.1038/nprot.2013.137 ↗
98. Henry, O. Y. F. et al. Organs-on-chips with integrated electrodes for trans-epithelial electrical resistance (TEER) measurements of human epithelial barrier function. Lab. Chip 17, 2264–2271 (2017).10.1039/C7LC00155J ↗
99. Matthiesen, I., Voulgaris, D., Nikolakopoulou, P., Winkler, T. E. & Herland, A. Continuous monitoring reveals protective effects of N-acetylcysteine amide on an isogenic microphysiological model of the neurovascular unit. Small 17, e2101785 (2021).10.1002/smll.202101785 ↗
100. Park, J. et al. A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer’s disease. Nat. Neurosci. 21, 941–951 (2018).10.1038/s41593-018-0175-4 ↗